[Influence of levocarnitine on heart function and endocrine among patients with heart failure]

To observe the efficacy of levocarnitine in treating elderly patients with chronic heart failure and to explore its impact on cardiac function and endocrine.

120 elderly patients with chronic heart failure were randomly divided into observation and control groups, with 60 cases of each. Patients in the control group were given conventional anti-heart failure drugs, and those in the observation group were given 3 g levocarnitine within 250 ml normal saline for intravenous infusion added to what had been given to the control group. Efficacy of the two groups was observed after 15 days.

The total effective rate in observation group was 95.0% , significantly higher than in the control group(83.3%), with statistically significant difference(χ(2) = 4.227, P < 0.05). After treatment, indicators as LVEDD, LVESD and LVESV in the observation group were significantly lower than those in the control group, with statistically significant differences(t = 2.256, 2.335, 2.277, P < 0.05). The LVEF values were significantly higher than in the control group after treatment, with statistically significant difference(t = 2.364, P < 0.05). Serum NT-pro-BNP, creatinine and cystatin C values in the observation group after treatment appeared significant reduction, when compared to the control group, and the difference was statistically significant(t = 2.339, 2.289, 2.315, P < 0.05).

Levocarnitine could significantly improve the cardiac function, and reduce the levels of serum NT-pro-BNP, creatinine and cystatin C. Our results suggested that it was worthwhile to promote large-scale clinical trials of this kind.